Viridian Therapeutics (VRDN) AI Stock Analysis

• Market Cap: $2.10B
• Dividend Yield: N/A
• Average Volume (3M): 814.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: 23340.07%
• EPS Growth: 18.06%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 93,093,030
• 10 Day Avg. Volume: 1,087,693
• 30 Day Avg. Volume: 814,586
• PEG Ratio: 0.19
• Price to Book (P/B): 1.94
• Price to Sales (P/S): 4309.19
• P/FCF Ratio: -5.59
• Enterprise Value/Market Cap: 0.38
• Enterprise Value/Revenue: 11.15
• Enterprise Value/Gross Profit: 11.15
• Enterprise Value/Ebitda: -2.64
• 1Y Price Target: $39.84
• Price Target Upside: 25.60% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: $33.00 ▲(4.04% Upside)

Viridian Therapeutics' stock score is primarily influenced by its strong technical momentum, despite financial challenges. The company's financial performance is weak due to ongoing losses and cash flow issues, but the technical indicators show bullish trends. Valuation remains a concern with a negative P/E ratio, reflecting the company's current unprofitability.

Positive Factors

Revenue Growth

The company's substantial revenue growth indicates strong market demand for its products, which can lead to increased market share and long-term sustainability.

Low Leverage

Low leverage provides financial stability and flexibility, allowing the company to invest in growth opportunities without the burden of high debt costs.

Innovative Product Pipeline

A focus on innovative therapies for rare diseases positions the company as a leader in niche markets, potentially leading to high-margin products and competitive advantage.

Negative Factors

Profitability Concerns

Ongoing profitability issues can hinder the company's ability to reinvest in R&D and may require additional capital raises, diluting shareholder value.

Cash Flow Challenges

Negative cash flow limits the company's ability to fund operations and growth initiatives internally, increasing reliance on external financing.

Operating Losses

High operating losses reflect the costs associated with development stages, which can strain financial resources and delay profitability.

Viridian Therapeutics Business Overview & Revenue Model

Company Description

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Viridian Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company's revenue model includes potential sales from approved drugs, milestone payments from partnerships, and royalties on product sales. Key revenue streams may arise from collaborations with larger pharmaceutical companies that provide funding for research and development in exchange for future profits or product rights. Additionally, Viridian may seek to monetize its product pipeline through licensing agreements or partnerships that allow it to share development costs and risks while gaining access to broader distribution channels.

Viridian Therapeutics Financial Statement Overview

Summary

Viridian Therapeutics is experiencing significant revenue growth, but profitability and cash flow remain challenging. The balance sheet is stable with low leverage, yet ongoing losses could pose risks if not addressed. The company should focus on improving operational efficiency and cash flow management.

Income Statement

Viridian Therapeutics shows significant revenue growth in the TTM period, but profitability remains a major concern with negative net profit margins and EBIT margins. The company is experiencing high operating losses, which is typical for biotechnology firms in the development phase.

Balance Sheet

The company maintains a low debt-to-equity ratio, indicating conservative leverage. However, the negative return on equity reflects ongoing losses, which could be a risk if not managed well. The equity ratio is stable, suggesting a solid asset base relative to liabilities.

Cash Flow

Free cash flow is negative, but there is slight growth in the TTM period. The operating cash flow to net income ratio is unfavorable, indicating cash flow challenges. The company needs to improve cash generation to support its operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	70.79M	302.00K	314.00K	1.77M	2.96M	1.05M
Gross Profit	70.79M	302.00K	314.00K	1.77M	2.96M	-27.25M
EBITDA	-298.99M	-265.66M	-235.37M	-129.13M	-79.29M	-40.28M
Net Income	-301.97M	-269.95M	-237.73M	-129.87M	-79.41M	-110.72M
Balance Sheet
Total Assets	577.14M	742.40M	490.42M	435.09M	203.71M	131.25M
Cash, Cash Equivalents and Short-Term Investments	490.90M	717.58M	477.37M	424.55M	196.97M	127.64M
Total Debt	23.82M	21.09M	21.05M	5.26M	520.00K	455.00K
Total Liabilities	74.17M	70.76M	48.40M	40.03M	15.99M	11.22M
Stockholders Equity	502.97M	671.64M	442.02M	395.06M	187.72M	120.04M
Cash Flow
Free Cash Flow	-326.34M	-232.83M	-185.07M	-94.64M	-54.92M	-29.82M
Operating Cash Flow	-325.97M	-232.32M	-184.17M	-93.84M	-54.58M	-29.78M
Investing Cash Flow	238.94M	-228.65M	-94.25M	-115.13M	-74.29M	-50.48M
Financing Cash Flow	56.36M	457.74M	225.67M	322.24M	125.28M	101.31M

Viridian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 31.72
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Positive. The current price of 31.72 is above the 20-day moving average (MA) of 27.79, above the 50-day MA of 24.01, and above the 200-day MA of 17.66, indicating a bullish trend. The MACD of 2.22 indicates Negative momentum. The RSI at 76.63 is Negative, neither overbought nor oversold. The STOCH value of 81.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VRDN.

Viridian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	59 Neutral	$2.10B	-5.29	-47.40%	―	23340.07%	18.06%
JANX	56 Neutral	$2.09B	―	-12.48%	―	-23.37%	-42.45%
DNTH	55 Neutral	$1.32B	-10.20	-28.57%	―	-42.64%	-39.78%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHVS	42 Neutral	$1.78B	―	-51.81%	―	―	-20.08%
EWTX	40 Underperform	$2.70B	―	-30.02%	―	―	-5.73%
BHVN	40 Underperform	$1.00B	―	-522.08%	―	―	18.76%

Viridian Therapeutics Corporate Events

Viridian Therapeutics Advances Toward Profitability with Strategic Moves

Viridian Therapeutics, Inc. is a biotechnology company dedicated to discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, with a focus on thyroid eye disease (TED) and neonatal Fc receptor (FcRn) inhibitors.

Viridian Therapeutics’ Promising Phase 3 Trial for Thyroid Eye Disease

Viridian Therapeutics, Inc. is conducting a Phase 3 clinical trial titled ‘A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003 Administered Subcutaneously in Participants With Thyroid Eye Disease (TED).’ The study aims to assess the safety, tolerability, and pharmacokinetics of VRDN-003, a humanized monoclonal antibody targeting the IGF-1 receptor, in individuals with Thyroid Eye Disease. This trial is significant as it could offer a new therapeutic option for TED, a condition with limited treatment options.

Viridian Therapeutics Advances VRDN-003 Study for Thyroid Eye Disease

Viridian Therapeutics, Inc. is conducting a clinical study titled A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED). The study aims to evaluate the safety and tolerability of VRDN-003, a potential treatment for TED, a condition that affects the eyes of people with thyroid disorders. This study is significant as it could lead to a new therapeutic option for TED patients.

Viridian Therapeutics Announces Stock Sale Agreement

On October 21, 2025, Viridian Therapeutics announced an underwriting agreement for the sale of 11,425,000 shares of common stock at $22.00 per share, potentially raising approximately $251.35 million. The proceeds, combined with other financial resources, are expected to fund the company’s operations, including anticipated revenue from product sales and milestone payments, although the company acknowledges potential risks and uncertainties in its financial projections.

The most recent analyst rating on (VRDN) stock is a Hold with a $24.50 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.

Viridian Therapeutics Secures $300M Deal with DRI Healthcare

On October 17, 2025, Viridian Therapeutics entered into a Purchase and Sale Agreement with DRI Healthcare Acquisitions, selling rights to certain revenue streams in the U.S. for up to $300 million. This agreement includes payments contingent on achieving specific clinical and regulatory milestones for its products VRDN-003 and veligrotug. Additionally, Viridian amended its Loan and Security Agreement with Hercules Capital, securing a new term loan facility of up to $300 million, structured in tranches contingent on regulatory and revenue milestones, with a maturity date set for October 17, 2030.

The most recent analyst rating on (VRDN) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.